Phase II Study of Cabozantinib and Pembrolizumab in Patients with Metastatic Pancreatic Cancer
Summary
The purpose of this phase I study is to evaluate the safety and efficacy of cabozantinib and pembrolizumab in patients with metastatic pancreatic cancer.
General Information
NCT#: NCT05052723
Study ID: MCC-21-GI-117
Trial Phase: Phase II
Trial Sponsor: Joseph Kim
Therapies Used in This Trial: Cabozantinib, Pembrolizumab